anti-VEGFR2 antibody (ThromboGenics)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-VEGFR2 antibody (ThromboGenics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgium
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesOxurion Nv
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOxurion Nv
Active IndicationsN/A
Inactive IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A